March 22nd 2024
In an interview with Targeted Oncology, Julie Chang, MD, discussed the minimal residual disease-adapted study in patients with previously untreated mantle cell lymphoma and the key findings from the trial.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Pro Discusses Options for Patients With Advanced-Stage Hodgkin Lymphoma
October 10th 2019Barbara Pro, MD, spoke with a group of physicians during a <em>Targeted Oncology </em>live case-based peer perspectives discussion about the diagnosis, prognosis, and treatment of patients with Hodgkin lymphoma based on the case of a young woman with classic Hodgkin lymphoma.
Read More
Fitting Zanubrutinib into the Treatment Landscape for Mantle Cell Lymphoma
September 27th 2019Michael Wang, MD, discusses the potential role for the next-generation Bruton's tyrosine kinase inhibitor zanubrutinib compared with first- and second-generation BTK inhibitors for the treatment of patients with mantle cell lymphoma.
Watch
Ten-Year Analysis Confirms Poor Prognosis in TP53-Mutant Mantle Cell Lymphoma
September 26th 2019In an interview with Targeted Oncology, Ezzat Elhassadi, MD, discussed the results from this analysis and how the presence of a TP53 mutation can impact the survival of patients with MCL. He also highlighted the remaining challenges in this space and how these challenges can be overcome.
Read More
Low-Dose Radiation Effective With/Without Concurrent Chemotherapy in R/R Mantle Cell Lymphoma
September 5th 2019In an interview with Targeted Oncology, Matthew S. Ning, MD, MPH, discussed the role for low-dose radiotherapy as treatment of patients with relapsed/refractory MCL, according to the findings from a recent analysis. He also highlighted how a multidisciplinary approach can impact the treatment of patients with MCL.
Read More
Neelapu Discusses Toxicities Associated With CAR T Cells in Large B-Cell Lymphomas
August 29th 2019In an interview with Targeted Oncology, Sattva S. Neelapu, MD, discussed the evolving role for CAR T-cell therapy in patients with B-cell lymphomas. He also highlighted the toxicities commonly associated with these therapies and how physicians can treat these AEs as they arise.
Read More
Exploring Approaches to Treating Different Subgroups of Mantle Cell Lymphoma
August 26th 2019Peter Martin, MD, discusses the differences between subgroups of mantle cell lymphoma. MCL is a heterogenous disease, and in the World Health Organization classification of lymphoid neoplasms, MCL has a leukemia non-nodal presentation, says Martin.
Watch
FDA Grants Priority Review to Zanubrutinib for Previously Treated Mantle Cell Lymphoma
August 22nd 2019The FDA has granted a New Drug Application for zanubrutinib a priority review for the treatment of patients with mantle cell lymphoma who have previously received at least 1 prior treatment.
Read More
Triplet Combination With Vorinostat Shows High Response Rate in Frontline MCL
August 20th 2019A combination of vorinostat, cladribine, and rituximab demonstrated high, durable rates of complete response in patients with previously untreated mantle cell lymphoma, according to the results of a phase I/II trial of the triplet regimen in patients with non-Hodgkin lymphoma.<br />
Read More
Assessing the Role CAR T-cell Therapy Plays in Mantle Cell Lymphoma Treatment in ZUMA-2 Trial
July 31st 2019Kieron Dunleavy, MD, discussed current approaches to treating patients with MCL, highlighting peer discussions on the subject and information about the ZUMA-2 trial, in an interview with <em>Targeted Oncology</em>.
Read More
Sequencing Treatment Options in Mantle Cell Lymphoma
July 26th 2019Simon Rule, MD, PhD, discusses the current treatment approaches for patients with mantle cell lymphoma in both the United Kingdom and the United States. He says treatment strategies are pretty well established on both sides of the Atlantic Ocean.
Watch
Frontline Therapy for Mantle Cell Lymphoma Should Be Individualized Expert Urges
July 24th 2019In an interview with <em>Targeted Oncology</em>, Peter Martin, MD, assistant professor of medicine, Division of Hematology/Oncology, Weil Cornell Medicine, recounts physician crossfire discussions related to frontline MCL treatment and provides his own expert opinion on the subject.
Read More
Zanubrutinib Confirmed Highly Active for Relapsed/Refractory MCL
July 16th 2019A single-arm, multicenter phase II trial held in China analyzed the Bruton’s tyrosine kinase inhibitor zanubrutinib for treatment of patients with relapsed/refractory mantle cell lymphoma. Previously, the investigational BTK inhibitor gained a breakthrough designation from the FDA based on early results from the phase II trial that showed zanubrutinib to be highly active.<br />
Read More
Ibrutinib Maintenance Appears Safe in MCL Following Induction Therapy
June 25th 2019Ibrutinib as a maintenance therapy for patients with mantle cell lymphoma who respond to frontline induction therapy with or without autologous stem cell transplant appeared safe and feasible, according to the results of a recent study presented at the 2019 ASCO Annual Meeting.
Read More
Different Therapeutic Options Required for Subtypes in Mantle Cell Lymphoma
June 25th 2019Ezzat Elhassadi, MD, a consultant hematologist at the University Hospital Waterford in Ireland, discusses the therapeutic approach for different subtypes of mantle cell lymphoma. MCL is a spectrum of diseases that should be treated differently, he says.
Watch
R-BAC Combination Active Following BTK Inhibitor Relapse in Patients With MCL
June 20th 2019In an interview with <em>Targeted Oncology</em>, Rory McCulloch, MD, discussed the results from a retrospective analysis for R-BAC treatment following relapse on a BTK inhibitor in patients with mantle cell lymphoma.
Read More
Small Molecule Demonstrates Activity Against Ibrutinib-Resistant MCL
May 20th 2019Preclinical data suggest that the small molecule IACS-10759, which targets the oxidative phosphorylation and glutaminolysis pathways, may play a critical role in overcoming resistance to ibrutinib in mantle cell lymphoma.
Read More
Flinn Analyzes Data from 5-Year Follow-Up of Phase III BRIGHT Trial in Frontline MCL
May 15th 2019In an interview with <em>Targeted Oncology</em>, Ian W. Flinn, MD, PhD, discussed the findings from the phase III BRIGHT trial for patients with MCL. He also highlighted the impact of BR in this patient population and other combinations under active investigation.
Read More
Cohen Reviews Treatment Decisions for Patient With Newly Diagnosed MCL
April 24th 2019During a <em>Targeted Oncology </em>live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, explained to a group of physicians the treatment considerations and decisions he makes when seeing a patient with mantle cell lymphoma in the clinic.
Read More
Study Confirms Initial Monitoring Strategy Effective in MCL
April 23rd 2019In a recent retrospective analysis, investigators found that initially observing patients with mantle cell lymphoma based solely on clinical criteria was an effective management strategy that did not compromise patient outcomes.
Read More